I  Georgia Research Alliance


     Office Locations:

191 Peachtree Street, NE, Suite 849
Atlanta, GA 30303
Phone: 404-332-9770



  • Early



  • Information Technology
  • Life Sciences & Healthcare



    GRA operates as an independent not-for-profit entity governed by leaders from industry and academia. While GRA receives a state appropriation for investment in university-based research opportunities, its small staff and lean operations are funded through foundation and industry contributions. In its first 19 years, GRA leveraged $525 million in state funding into $2.6 billion of additional federal and private investment. VentureLab is GRA's signature technology commercialization program. Launched in 2002, VentureLab helps build high-growth companies around laboratory discoveries at GRA's partner universities. VentureLab seeks out university-based research innovations, evaluates their commercial potential and provides resources to address the management, market and technology risks that come with new ventures. Each participating university -- Georgia Tech, Emory, the University of Georgia, Georgia State University and Georgia Health Sciences University -- has an active technology incubator with which VentureLab can partner. In the last five years through VentureLab, GRA has evaluated the commercial potential of more than 260 university inventions or discoveries and awarded VentureLab grants to form 107 active companies. At the end of 2010, these companies employed more than 640 professionals, had attracted $460.2 million in private equity investment and generated nearly $77 million in revenue.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Amy C. Moore Ph.D. Director
    Ashley F. Cornelison Project Manager
    C. Michael Cassidy President and CEO
    Greg Dane Director
    H. Lee Herron Vice President of Commercialization


    Recent Funding Events (trailing 12 months):







      Antios Therapeutics



      Series A


    Portfolio companies include:

      Antios Therapeutics
        web link

      ArunA Biomedical
        web link

      Axion Biosystems
        web link

      Body Surface Translations
        web link

        web link

        web link

      Clearside Biomedical
        web link

        web link

      Digital Vision
        web link

        web link

        web link

        web link

        web link

      MedShape Solutions
        web link

        web link

        web link

        web link

      REACH Health
        web link

        web link

        web link

        web link


    Recent News: